ZBIO
ZBIO
NASDAQ · Biotechnology

Zenas Biopharma Inc

$28.46
+0.08 (+0.28%)
As of Nov 7, 1:56 AM ET ·
Financial Highlights (FY 2026)
Revenue
14.26M
Net Income
-538,514,896
Gross Margin
—
Profit Margin
-3,777.4%
Rev Growth
—
D/E Ratio
0.32
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — 63.1% 63.1% 63.1%
Operating Margin -3,830.6% -0.1% -0.1% -0.1%
Profit Margin -3,777.4% -0.1% -0.1% -0.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 14.26M 140.52M 130.81M 124.82M
Gross Profit — 88.66M 82.54M 78.75M
Operating Income -546,189,752 -128,018 -131,088 -117,084
Net Income -538,514,896 -116,113 -126,311 -113,132
Gross Margin — 63.1% 63.1% 63.1%
Operating Margin -3,830.6% -0.1% -0.1% -0.1%
Profit Margin -3,777.4% -0.1% -0.1% -0.1%
Rev Growth — -3.7% +16.0% -9.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 222.42M 299.15M 339.29M 361.86M
Total Equity 685.01M 337.93M 370.10M 341.01M
D/E Ratio 0.32 0.89 0.92 1.06
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -546,020,485 -178,287 -168,053 -162,378
Free Cash Flow — -139,366 -118,293 -114,579